Cour

Reprogramming the immune system. Restoring lives. | COUR Pharma

Evanston, United States · Founded 2015 · $155.0M raised

Headquarters
Evanston
Employees
51–200
Founded
2015
Total Funding
$155.0M
Last Round
$50.0M Series BJun 2026
Rounds
2

About

COUR is a clinical-stage biotechnology company developing disease-modifying therapies for autoimmune diseases. Its proprietary COUR nanoparticle platform is designed to induce antigen-specific immune tolerance, targeting the root mechanisms of disease without broadly suppressing normal immune function. The company is advancing programs in primary biliary cholangitis, type 1 diabetes, myasthenia gravis, and celiac disease.

Summary

Cour is a Biotech company based in Evanston, United States, founded in 2015. It has raised $155.0M in total across 2 rounds, most recently a $50.0M Series B round in Jun 2026. Investors include Lumira Ventures, Alpha Wave Ventures and Bristol Myers Squibb.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series BSeries BJun 2026
$50.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cour on Indexed.vc
<a href="https://indexed.vc/companies/cour"><img src="https://indexed.vc/api/badge/company/cour" alt="Cour on Indexed.vc" width="260" height="76" /></a>